Magnús Karl Magnússon, prófessor


Magnús Karl Magnússon, prófessor við Læknadeild Háskóla Íslands 
 

Ég hef mikla reynslu af störfum innan skólans; ég hef gegnt stöðu prófessors við Læknadeild í tæp sextán ár og hef allan þann tíma sinnt mikilli kennslu og verið mjög virkur í rannsóknum. Ég hef víðtæka rannsóknarþjálfun og reynslu á sviði grunnvísinda læknisfræðinnar allt frá grunnnámi mínu, gegnum framhaldsnám í Bandaríkjunum og við Landspítalann áður en hóf störf við skólann. Auk þess hef ég víðtæka stjórnunarreynslu, var meðal annars forseti Læknadeildar í tvö tímabil, sem er ein stærsta deild skólans, og hef sinnt fjölmörgum öðrum stjórnunar- og nefndarstörfum innan háskóla- og vísindasamfélagsins og utan.

Rannsóknagátt
Orcid útgáfa

Námsgráður og sérnám 

  • 2000 – Lauk sérfræðinámi í blóðlækningum, NHLBI, National Institutes of Health
  • 1998 – Lauk ég sérfræðinámi í almennum lyflækngum í sérhæfðri akademískri sérnámsleið „Clinical Investigator Pathway“, University of Wisconsin-Madison
  • 1991 – Kandídatspróf, Háskóli Íslands, með valkvæðu aukaári þar sem ég vann við grunnrannsóknir

Starfsferill

  • 2009 – , Prófessor við Læknadeild, Háskóli Íslands
  • 2018 – , Íslensk Erfðagreining, rannsakandi.
    Hlutastarf við mannerfðafræði á sviði blóðsjúkdóma
  • 2002 – 2009, Sérfræðingur í blóðmeinafræði við rannsóknarsvið, Landspítali – háskólasjúkrahús
  • 2003 – 2009, Stundakennari við Læknadeild og Raunvísindadeild, Háskóli Íslands
  • 2000 – 2002, Rannsakandi við Blóðsjúkdómadeild, National Heart, Lung & Blood Institute, NIH

Stjórnun

Ég hef gegnt fjölmörgum stjórnunar- og nefndarstörfum. Ég var forseti Læknadeildar á árunum 2013-16 eftir að hafa gegnt stöðu varadeildarforseta (2011-13). Læknadeild er ein stærsta deild Háskólans með yfir 100 akademíska starfsmenn, margar námsleiðir (m.a. læknisfræði, sjúkraþjálfun, lífeindafræði, geislafræði) á öllum námsstigum og mikil umsvif í rannsóknum. Meðan ég var deildarforseti stýrði ég meðal annars fyrsta sjálfsmati deildarinnar sem var mjög flókin greiningar- og stefnumótunarvinna. Sem deildarforseti hafði ég leiðandi hlutverk á fjölmörgum sviðum, meðal annars mannaráðningum, flóknum störfum er snúa að samþættingu háskóla- og klínískra starfa stórs hóps akademískra starfsmanna deildarinnar og flóknum starfsmannamálum sem koma upp í svo stórri deild. Ég hef einnig verið formaður stjórna tveggja þverfaglegra eininga inna skólans; námsleið í Talmeinafræði (meistaranám)  og síðastliðin sex ár við Miðstöð í lýðheilsvísindum (MLV), en þar fer fram þverfræðilegt nám á meistara- og doktorsstigi í lýðheilsuvísindum, faraldsfræði og líftölfræði.

Ég hef auk þess víðtæka reynslu af nefndarstörfum og má þar nefna mikilvæg nefndarstörf á sviði vísinda, svo sem seta í fagráði Heilbrigðis-og lífvísinda fyrir Rannsóknarsjóð VTR á árunum 2004-2008 og ég var formaður fagráðsins frá 2005-2008.  Ég var einnig landsfulltrúi í sjöundu Rammaáætlun Evrópusambandsins (2006-2008). Á árunum 2014-2021 sat ég í fimm manna verðlaunanefnd (valnefnd) Anders Jahre læknisfræðiverðlaunanna (Anders Jahre’s Awards for Medical Research), en þau eru ein virtustu verðlaun sem veitt er á sviði læknavísinda á Norðurlöndunum. Ég hef síðastliðin tvö ár einnig verið formaður stjórnar Vísindasjóðs Krabbameinsfélagsins en sjóðurinn hefur á undanförnum sjö árum veitt vísindastyrki til krabbameinsrannsókna fyrir yfir hálfan milljarð króna. Á síðasta ári var ég skipaður formaður nýrrar faglegrar ritstjórnar Vísindavefs Háskóla Íslands. Að lokum má nefna nefndarstörf á vegum ráðuneyta svo sem nefnd sem kom að samningu lagafrumvarps um stofnfrumurannsóknir og lagafrumvarp um vísindarannsóknir á heilbrigðissvið auk nefndar um nýtingu erfðaupplýsinga.

Í gegnum þessi og fleiri stjórnunar- og nefndarstörf hef ég öðlast mikla reynslu af stjórnun og stefnumótun. Einnig hafa þessi störf ásamt umfangsmikilli reynslu af stjórnun flókinna rannsóknarverkefna kallað á leiðtogahæfileika og ríka samskiptahæfni.

  1. Tragante V & Magnusson MK Understanding fibrinogen genetics. Blood 144, 2164-2165 (2024).
  2. Steingrimsson E & Magnusson MK [The Nobel prize in medicine – microRNA and gene regulation]. Laeknabladid 110, 557 (2024).
  3. Stefansson OA, Sigurpalsdottir BD, Rognvaldsson S, Halldorsson GH, Juliusson K, Sveinbjornsson G, … (6 additonal authors)…, Magnusson MK, et al (19 additional authors). The correlation between CpG methylation and gene expression is driven by sequence variants. Nat Genet. 2024;56(8):1624-31.
  4. Stacey SN, Zink F, Halldorsson GH, Stefansdottir L, Gudjonsson SA, Einarsson G, … (9 additonal authors)…, Magnusson MK, et al (15 additional authors). Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis. Nat Genet. 2023;55(12):2149-59.
  5. Jensson BO, Arnadottir GA, Katrinardottir H, Fridriksdottir R, Helgason H, Oddsson A, …(15 additonal authors)…, Magnusson MK, et al (21 additional authors). Actionable Genotypes and Their Association with Life Span in Iceland. N Engl J Med. 2023;389(19):1741-52.
  6. Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OT, Gunnarsdottir K, …(10 additonal authors)…, Magnusson MK, et al (16 additional authors). Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023;622(7982):348-58.
  7. Wheeler MM, Stilp AM, Rao S, Halldorsson BV, Beyter D, Wen J, …(46 additonal authors)…, Magnusson MK, et al (5 additional authors). Whole genome sequencing identifies structural variants contributing to hematologic traits in the NHLBI TOPMed program. Nat Commun. 2022;13(1):7592.
  8. Oskarsson GR, Magnusson MK**, Oddsson A, Jensson BO, Fridriksdottir R, Arnadottir GA, et al (28 additional authors). Genetic architecture of band neutrophil fraction in Iceland. Commun Biol. 2022;5(1):525.
  9. Gestsdottir E, Magnusson MK, Lund SH, Johannsdottir V, Jonsson T, Gudmundsson S, Halldordottir AM. Monitoring iron stores in Icelandic blood donors from 1997 through 2019. Transfus Med. 2022;32(2):128-34.
  10. Silvestri L, Magnusson MK. Iron biology: the balance matters. Semin Hematol. 2021;58(3):131.
  11. Mikaelsdottir E, Thorleifsson G, Stefansdottir L, Halldorsson G, Sigurdsson JK, Lund SH, …(5 additonal authors)…, Magnusson MK, et al (21 additional authors). Genetic variants associated with platelet count are predictive of human disease and physiological markers. Commun Biol. 2021;4(1):1132.
  12. Jonsson H, Magnusson OT, Melsted P, Berglund J, Agustsdottir AB, Eiriksdottir B, …(24 additonal authors)…, Magnusson MK, et al (16 additional authors). Molecular benchmarks of a SARS-CoV-2 epidemic. Nat Commun. 2021;12(1):3633.
  13. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, …(11 additonal authors)…, Magnusson MK, et al (22 additional authors). Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53(12):1712-21.
  14. Dowsett J, Ferkingstad E, Rasmussen LJH, Thorner LW, Magnusson MK, Sugden K, et al (23 additional authors). Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor. Commun Biol. 2021;4(1):655.
  15. Bell S*, Rigas AS*, Magnusson MK*, Ferkingstad E, Allara E, Bjornsdottir G, et al (55 additional authors). A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis. Commun Biol. 2021;4(1):156.
  16. Oskarsson GR*, Oddsson A*, Magnusson MK*, Kristjansson RP, Halldorsson GH, Ferkingstad E, et al. Predicted loss and gain of function mutations in ACO1 are associated with erythropoiesis. Commun Biol. 2020;3(1):189.
  17. Budkova Z, Sigurdardottir AK, Briem E, Bergthorsson JT, Sigurdsson S, Magnusson MK, et al (3 additional authors). Expression of ncRNAs on the DLK1-DIO3 Locus Is Associated With Basal and Mesenchymal Phenotype in Breast Epithelial Progenitor Cells. Front Cell Dev Biol. 2020;8:461.
  18. Magnusson MK. [The Nobel Prize in Medicine 2019 – The cellular oxygen sensing mechanism]. Laeknabladid. 2019;105(11):479.
  19. Ingason AB, Magnusson MK, Ragnarsson GB. [Opioid overdose following voriconazole treatment – case report]. Laeknabladid. 2019;105(7):335-7.
  20. Halldorsson H, Orrason AW, Oskarsdottir GN, Petursdottir A, Fridriksson BM, Magnusson MK, et al (2 additional authors). Improved long-term survival following pulmonary resections for non-small cell lung cancer: results of a nationwide study from Iceland. Ann Transl Med. 2019;7(5):88.
  21. Briem E, Budkova Z, Sigurdardottir AK, Hilmarsdottir B, Kricker J, Timp W, Magnusson MK, et al (2 additional authors). MiR-203a is differentially expressed during branching morphogenesis and EMT in breast progenitor cells and is a repressor of peroxidasin. Mech Dev. 2019;155:34-47.
  22. Oskarsson GR, Kristjansson RP, Lee AL, Sveinbjornsson G, Magnusson MK, Ivarsdottir EV, et al (17 additional authros). A truncating mutation in EPOR leads to hypo-responsiveness to erythropoietin with normal haemoglobin. Commun Biol. 2018;1:49.
  23. Jonsdottir T, Valdimarsdottir H, Tryggvadottir L, Lund SH, Thordardottir M, Magnusson MK, Valdimarsdottir U. [Views of Icelandic women towards genetic counseling – and testing of BRCA2 mutations]. Laeknabladid. 2018;104(6):289-96.
  24. Oskarsdottir AR, Gudmundsdottir BR, Indridason OS, Lund SH, Arnar DO, Bjornsson ES, Magnusson MK et al (4 additional authors). Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial. J Thromb Thrombolysis. 2017;43(4):550-61.
  25. Hilmarsdottir B, Briem E, Halldorsson S, Kricker J, Ingthorsson S, Gustafsdottir S, Maelandsmoe GM, Magnusson MK, Gudjonsson T. Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells. Cell Death Dis. 2017;8(5):e2769.
  26. Magnusson MK. [Medical education in Iceland, 140th anniversary[Editorial]]. Laeknabladid. 2016;102(12):537.
  27. Ingthorsson S, Andersen K, Hilmarsdottir B, Maelandsmo GM, Magnusson MK, Gudjonsson T. HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR. Oncogene. 2016;35(32):4244-55.
  28. Onundarson PT, Francis CW, Indridason OS, Arnar DO, Bjornsson ES, Magnusson MK, et al (6 additional authors). Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial. Lancet Haematol. 2015;2(6):e231-40.
  29. Magnusson MK. [Harnessing genetic information for health care]. Laeknabladid. 2015;101(5):239.
  30. Jonsdottir HR, Arason AJ, Palsson R, Franzdottir SR, Gudbjartsson T, Isaksson HJ, … (2 additional authors)…Magnusson MK. Basal cells of the human airways acquire mesenchymal traits in idiopathic pulmonary fibrosis and in culture. Lab Invest. 2015;95(12):1418-28.
  31. Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, …(3 additonal authors)…, Magnusson MK, et al (6 additional authors). KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol. 2015;33(6):634-42.
  32. Ingthorsson S, Hilmarsdottir B, Kricker J, Magnusson MK, Gudjonsson T. Context-Dependent Function of Myoepithelial Cells in Breast Morphogenesis and Neoplasia. Curr Mol Biol Rep. 2015;1(4):168-74.
  33. Hilmarsdottir B, Briem E, Sigurdsson V, Franzdottir SR, Ringner M, Arason AJ, Bergthorsson JT, Magnusson MK, Gudjonsson T. MicroRNA-200c-141 and ∆Np63 are required for breast epithelial differentiation and branching morphogenesis. Dev Biol. 2015;403(2):150-61.
  34. Halldorsson H, Arason AJ, Sigurethardottir M, Gargiulo P, Magnusson MK, Gudjonsson T, Petersen H. [Recurrent tumor growth in the right maxilla–a rare case of an inflammatory myofibroblastic tumor]. Laeknabladid. 2015;101(1):19-23.
  35. Bragadottir G, Birgisdottir ER, Gudmundsdottir BR, Hilmarsdottir B, Vidarsson B, Magnusson MK, et al (4 additional authors). Clinical phenotype in heterozygote and biallelic Bernard-Soulier syndrome–a case control study. Am J Hematol. 2015;90(2):149-55.
  36. Hilmarsdottir B, Briem E, Bergthorsson JT, Magnusson MK, Gudjonsson T. Functional Role of the microRNA-200 Family in Breast Morphogenesis and Neoplasia. Genes (Basel). 2014;5(3):804-20.
  37. Arason AJ, Jonsdottir HR, Halldorsson S, Benediktsdottir BE, Bergthorsson JT, Ingthorsson S, …(3 additional authors) Magnusson MK. deltaNp63 has a role in maintaining epithelial integrity in airway epithelium. Plos One. 2014;9(2):e88683.
  38. Thormar HG, Gudmundsson B, Eiriksdottir F, Kil S, Gunnarsson GH, Magnusson MK, et al (2 additional authors). Importance of the efficiency of double-stranded DNA formation in cDNA synthesis for the imprecision of microarray expression analysis. Clin Chem. 2013;59(4):667-74.
  39. Sigurdsson V, Ingthorsson S, Hilmarsdottir B, Gustafsdottir SM, Franzdottir SR, Arason AJ, Steingrimsson E, Magnusson MK**, Gudjonsson MK**. Expression and functional role of sprouty-2 in breast morphogenesis. Plos One. 2013;8(4):e60798.
  40. Magnusson MK. [Investing in knowledge for the future]. Laeknabladid. 2013;99(12):555.
  41. Bergthorsson JT, Magnusson MK, Gudjonsson T. Endothelial-rich microenvironment supports growth and branching morphogenesis of prostate epithelial cells. Prostate. 2013;73(8):884-96.
  42. Magnusson MK. [Genetically modified plants; a threat to human health?]. Laeknabladid. 2012;98(11):577.
  43. Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen SE, Brabec P, …(6 additonal authors)…, Magnusson MK, et al (6 additional authors). Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265-74.
  44. Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, …(53 additonal authors)…, Magnusson MK, et al (23 additional authors). Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60(8):722-9.
  45. Sigurdsson V, Hilmarsdottir B, Sigmundsdottir H, Fridriksdottir AJ, Ringner M, Villadsen R, …(3 additonal authors)…, Magnusson MK, Gudjonsson T. Endothelial induced EMT in breast epithelial cells with stem cell properties. Plos One. 2011;6(9):e23833.
  46. Ingthorsson S, Halldorsson T, Sigurdsson V, Friethriksdottir AJ, Bodvarsdottir SK, Steinarsdottir M, Johannsson O, Magnusson MK, et al (2 additional authors).. Selection for EGFR gene amplification in a breast epithelial cell line with basal-like phenotype and hereditary background. In Vitro Cell Dev Biol Anim. 2011;47(2):139-48.
  47. Tryggvason G, Hilmarsdottir B, Gunnarsson GH, Jonsson JJ, Jonasson JG, Magnusson MK. Tyrosine kinase mutations in gastrointestinal stromal tumors in a nation-wide study in Iceland. APMIS. 2010;118(9):648-56.
  48. Ingthorsson S, Sigurdsson V, Fridriksdottir A, Jr., Jonasson JG, Kjartansson J, Magnusson MK, Gudjonsson T. Endothelial cells stimulate growth of normal and cancerous breast epithelial cells in 3D culture. BMC Res Notes. 2010;3:184.
  49. Gretarsdottir S, Baas AF, Thorleifsson G, Holm H, den Heijer M, de Vries JP, …(79 additonal authors)…, Magnusson MK, et al (16 additional authors).. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet. 2010;42(8):692-7.
  50. Franzdottir SR, Axelsson IT, Arason AJ, Baldursson O, Gudjonsson T, Magnusson MK. Airway branching morphogenesis in three dimensional culture. Respir Res. 2010;11(1):162.
  51. Tryggvason G, Kristmundsson T, Orvar K, Jonasson JG, Magnusson MK, Gislason HG. Clinical study on gastrointestinal stromal tumors (GIST) in Iceland, 1990-2003. Dig Dis Sci. 2007;52(9):2249-53.
  52. Hsu JC, Chang J, Wang T, Steingrimsson E, Magnusson MK, Bergsteinsdottir K. Statistically designing microarrays and microarray experiments to enhance sensitivity and specificity. Brief Bioinform. 2007;8(1):22-31.
  53. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al (2 additional authors). Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105(6):2473-9.
  54. D’Ambrosio C, Akin C, Wu Y, Magnusson MK, Metcalfe DD. Gene expression analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers. J Allergy Clin Immunol. 2003;112(6):1162-70.
  55. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 2002;100(3):1088-91.
  56. Panetti TS, Magnusson MK, Peyruchaud O, Zhang Q, Cooke ME, Sakai T, Mosher DF. Modulation of cell interactions with extracellular matrix by lysophosphatidic acid and sphingosine 1-phosphate. Prostaglandins Other Lipid Mediat. 2001;64(1-4):93-106.
  57. Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, Dunbar CE. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood. 2001;98(8):2518-25.
  58. Zhang Q, Peyruchaud O, French KJ, Magnusson MK, Mosher DF. Sphingosine 1-phosphate stimulates fibronectin matrix assembly through a Rho-dependent signal pathway. Blood. 1999;93(9):2984-90.
  59. Magnusson MK, Mosher DF. Fibronectin: structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol. 1998;18(9):1363-70.
  60. Zhang Q*, Magnusson MK*, Mosher DF. Lysophosphatidic acid and microtubule-destabilizing agents stimulate fibronectin matrix assembly through Rho-dependent actin stress fiber formation and cell contraction. Mol Biol Cell. 1997;8(8):1415-25.
  61. Magnusson MK, Thorgeirsson G. Iron metabolism and coronary heart disease. Primary Cardiology. 1995;21(12):17-20.
  62. Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation. 1994;89(1):102-8.
  63. Halldorsson H, Magnusson MK, Thorgeirsson G. Different mechanisms of homologous and heterologous desensitization of thrombin-induced endothelial prostacyclin production. Eur J Pharmacol. 1991;208(3):193-8.
  64. Magnusson MK, Halldorsson H, Kjeld M, Thorgeirsson G. Endothelial inositol phosphate generation and prostacyclin production in response to G-protein activation by AlF4. Biochem J. 1989;264(3):703-11.
  65. Magnusson MK. Slökunarboð æðaþels (Endothelium-derived relaxing factor,Review article). Laeknaneminn. 1988;41(1):2-29.

* co-first authors

** co-corresponding authors

  • +354-825 5091
  • magnuskm@hi.is

Magnús Karl Magnússon, prófessor

© Allur réttur áskilinn